A randomized, multicenter, open-label study to comparison of tenofovir monotherapy with entecavir-adefovir combination in suboptimal responder for lamivudine plus adefovir rescue therapy in chronic hepatitis B patients with YMDD mutation

Trial Profile

A randomized, multicenter, open-label study to comparison of tenofovir monotherapy with entecavir-adefovir combination in suboptimal responder for lamivudine plus adefovir rescue therapy in chronic hepatitis B patients with YMDD mutation

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Tenofovir (Primary) ; Adefovir; Entecavir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms TEAM
  • Most Recent Events

    • 15 Nov 2016 Primary endpoint (Proportion of patients with complete virological response (HBV-DNA 20 IU/mL) at week 96) has been met.
    • 07 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top